ArticlePloS one2026
Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research trends in depression associated with gynecologic cancers from 2006 to 2025: a multidatabase bibliometric and visual analysis.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemale-specific cancers represent a substantial public health challenge in China. This study was designed to evaluate temporal trends and generate future projections of the burden associated with female-specific cancers in China from 1990 to 2023.
methodsData on incidence, mortality, and disability-adjusted life-years (DALYs) attributable to breast, cervical, uterine, and ovarian cancers among women in China were extracted from the Global Burden of Disease (GBD) 2023 database. Joinpoint analysis was used to assess temporal trends, whereas decomposition analysis was applied to quantify the contributions of epidemiological changes, population growth, and ageing to changes in disease burden; a Bayesian age-period-cohort (BAPC) model was further used to project trends in disease burden over the next 15 years.
resultsBetween 1990 and 2023, all age-standardized rates (ASRs) of female-specific cancers in China declined except for the age-standardized incidence rate (ASIR) of breast cancer, which increased from 24.54 (95% uncertainty interval [UI]: 19.7-30.79) per 100,000 in 1990 to 31.62 (95% UI: 25.4-38.22) per 100,000 in 2023. The absolute disease burden increased, with 342,725 (95% UI: 270,872-413,171) new breast cancer cases in 2023, representing a 187.24% increase. In contrast, the numbers of new cases of cervical, uterine, and ovarian cancers were 124,686 (95% UI: 77,638-165,722), 74,990 (95% UI: 53,630-119,885), and 38,969 (95% UI: 31,914-46,805), respectively, with corresponding increases of 43.63%, 82.97%, and 61.76%. Population aging and growth were the main contributing factors, and the BAPC model projected that the absolute disease burden of all four female-specific cancers would continue to increase in the future.
conclusionThe burden of female-specific cancers in China remains substantial, underscoring the urgent need to develop targeted prevention and intervention strategies to mitigate this burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.